RLMD

Relmada Therapeutics, Inc. Common Stock

6.54

USD

RLMD Earnings Reports

Positive Surprise Ratio

RLMD beat 10 of 23 last estimates.

43%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$0.14

Implied change from Q4 25 (Revenue/ EPS)

-50.00%

Implied change from Q1 25 (Revenue/ EPS)

-75.44%

Relmada Therapeutics, Inc. Common Stock earnings per share and revenue

On Mar 19, 2026, RLMD reported earnings of -0.28 USD per share (EPS) for Q4 25, missing the estimate of -0.14 USD, resulting in a -103.08% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.88% price change (close before vs. close after earnings).

Looking ahead to Q1 26, -- analysts forecast an EPS of -0.14 USD, with revenue projected to reach -- USD, implying an decrease of -50.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Context Therapeutics Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.14

Surprise

-29.39%

Avalo Therapeutics, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$1.49

Actual

-$1.12

Surprise

+24.33%

Journey Medical Corporation Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.04

Surprise

+31.86%

Surrozen, Inc. Common

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$1.21

Actual

Surprise

Achieve Life Sciences, Inc.

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.12%

Vivani Medical, Inc. Common Stock (DE)

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.10

Actual

-$0.09

Surprise

Pyxis Oncology, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.28

Surprise

+15.55%

Acrivon Therapeutics, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.47

Actual

-$0.52

Surprise

-9.34%

Fractyl Health, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

$0.15

Surprise

+181.70%

NRX Pharmaceuticals, Inc. Common Stock

Report Date

Mar 23, 2026 For Q4 25

Estimate

$0.00

Actual

-$0.01

Surprise

-361.54%

FAQ

What were Relmada Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Relmada Therapeutics, Inc. Common Stock reported EPS of -$0.28, missing estimates by -103.08%, and revenue of $0.00, 0% as expectations.

How did the market react to Relmada Therapeutics, Inc. Common Stock's Q4 2025 earnings?

The stock price moved down -2.88%, changed from $6.25 before the earnings release to $6.07 the day after.

When is Relmada Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for Relmada Therapeutics, Inc. Common Stock's next earnings report?

Based on -- analysts, Relmada Therapeutics, Inc. Common Stock is expected to report EPS of -$0.14 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.